Zobrazeno 1 - 10
of 85
pro vyhledávání: '"Gregory B Lesinski"'
Autor:
Kristen K. Ciombor, Yoanna Pumpalova, Christina Wu, Tanios Bekaii-Saab, Mohamad Bassam Sonbol, Jordan Berlin, Gregory B. Lesinski, Zhengjia Chen, Bassel F. El-Rayes, Ibrahim Halil Sahin, Amber Draper, Subir Goyal, Sigurdis Haraldsdottir, Satya Das, Daniel H. Ahn
Publikováno v:
Oncologist
Background Immune checkpoint inhibitor (ICI) therapy is highly effective in metastatic mismatch repair-deficient (MMR-D) colorectal cancer (CRC). In this study, we evaluated molecular and clinical predictors of ICI response in MMR-D CRC. Materials an
Autor:
Gregory B. Lesinski, Ibrahim Halil Sahin, Sujata R. Kane, Clifford J. Gunthel, Jessica Guadagno, Edith Brutcher, Christina Wu, Bassel F. El-Rayes, Katherine Emilie Rhoades Smith
Publikováno v:
JCO Oncology Practice. 16:319-325
Recent studies have identified durable responses with the use of immune checkpoint inhibitors in patients with mismatch repair–deficient (MMR-D)/microsatellite instability–high (MSI-H) metastatic colorectal cancer (CRC). The dramatic improvement
Autor:
Mehmet Akce, Gregory B. Lesinski, Christina Wu, Olatunji B. Alese, Bassel F. El-Rayes, Ibrahim Halil Sahin, Walid L. Shaib
Publikováno v:
British Journal of Cancer
Metastatic colorectal cancer (CRC) with a mismatch repair-deficiency (MMR-D)/microsatellite instability-high (MSI-H) phenotype carries unique characteristics such as increased tumour mutational burden and tumour-infiltrating lymphocytes. Studies have
Autor:
Edmund K. Waller, Maria Cardenas, Gregory B. Lesinski, Bassel F. El-Rayes, Jingru Zhu, Mohammad Y. Zaidi, Shuhua Wang, Brian S. Robinson, Michael B. Ware, Susan N. Thomas, Yuan Liu, Tenzin Passang Fnu, Shanmuganathan Chandrakasan, Sruthi Ravindranathan, Jian-Ming Li, Alan B. Frey, Rohan K. Dhamsania, Sanjeev Gumber, Anish Majumdar, Haydn T. Kissick
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundPaucity of T cells in the immune privileged tumor microenvironment (TME) of pancreatic ductal adenocarcinoma (PDAC) is a major reason that PDAC is refractory to immune checkpoint blockade.1 In this study, we show that human PDAC tumors over
Autor:
Juan M. Sarmiento, Shishir K. Maithel, Cameron Herting, Gregory B. Lesinski, Chrystal M. Paulos, Maggie Phillips, Megan M. Wyatt, Thomas A. Mace, Michael B. Ware, Bassel F. El-Rayes
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundPancreatic ductal adenocarcinoma (PDAC) is refractory to immunotherapy due in part to cellular cross-talk with cancer associated fibroblasts (CAFs). These interactions shape the microenvironment in a manner that is profoundly immunosuppress
Autor:
Katerina Mary Zakka, Bassel F. El-Rayes, Gregory B. Lesinski, Jerome C. Landry, Ganji Purnachandra Nagaraju, Walid L. Shaib
Publikováno v:
International Journal of Cancer. 145:1529-1537
Resistance of pancreatic ductal adenocarcinoma (PDAC) to radiotherapy and chemotherapy represents a significant clinical issue. Although the mechanisms of resistance are multi-faceted, client proteins of heat shock protein 90 (HSP90) such as hypoxia
Autor:
Wanqi Chen, Dong M. Shin, Sreenivas Nannapaneni, Andreas Wieland, Rafi Ahmed, Gregory B. Lesinski, Mihir R. Patel, Christopher C. Griffith, Zhengjia Chen, Zhuo Georgia Chen, Nabil F. Saba
Publikováno v:
Head and Neck Pathology. 13:304-312
This study addresses the hypothesis that IL-6/STAT3 signaling is of clinical relevance in oropharyngeal squamous cell carcinoma (OPSCC). We evaluated relationships between key components of this pathway in tumors from a unique cohort of n = 59 fully
Autor:
Matthew R. Farren, Yan Tong, Safi Shahda, Cameron Herting, Tanios Bekaii-Saab, Gregory B. Lesinski, Bert H. O'Neil, Bassel F. El-Rayes, Ziyue Liu, Christina Wu, Walid L. Shaib, Thomas A. Mace, Christopher McQuinn, Anne M. Noonan
Publikováno v:
Cancer Immunol Immunother
Modified FOLFOX6 is an established therapy for patients with metastatic colorectal cancer (mCRC). We conducted a single-arm phase Ib study to address the hypothesis that addition of pembrolizumab to this regimen could safely and effectively improve p
Autor:
Deon B. Doxie, Bassel F. El-Rayes, Gregory B. Lesinski, Olatunji B. Alese, Amanda Ruggieri, Cameron Herting, Walid L. Shaib, Mohammad Y. Zaidi, Kavita M. Dhodapkar, Shishir K. Maithel, Mehmet Akce, Christina Wu, Matthew R. Farren, Michael B. Ware, Rafi Ahmed, Yuchen Zhang, Madhav V. Dhodapkar, Juan M. Sarmiento
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Background Both pancreatic ductal adenocarcinoma (PDAC) and metastatic colorectal cancer (mCRC) have yet to widely benefit from T cell-targeted immunotherapy and have universally poor prognoses. Thus, enhancing the activity of immunotherapy is a high
Autor:
Gregory B. Lesinski, Christina Wu, Hanna Hong, Jonathan M. Hernandez, Tahsin M Khan, Alexander J Rossi
Publikováno v:
Annals of Surgical Oncology. 28:4098-4099